REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Dr.Max 41 S.R.O. (Slovakia)

Main Activities: Pharmacies and Drug Stores | Department Stores
Secondary Activities: Lessors of Other Real Estate Property | Advertising Agencies | Office Administrative Services
Full name: Dr.Max 41 S.R.O. Profile Updated: July 14, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Dr.Max 41 S.R.O. is an enterprise in Slovakia, with the main office in Kosice. It operates in the Pharmacies and Drug Stores industry. The company was established on March 20, 2014. 10 - 19 (2025) employees currently work for Dr.Max 41 S.R.O.. The latest financial highlights indicate a net sales revenue increase of 22.89% in 2024. Its’ total assets recorded a growth of 0.26%. The net profit margin of Dr.Max 41 S.R.O. increased by 0.44% in 2024.

Headquarters
Moldavska cesta, 8/A
Kosice; Kosicky; Postal Code: 04011

Contact Details: Purchase the Dr.Max 41 S.R.O. report to view the information.

Basic Information
Total Employees:
Purchase the Dr.Max 41 S.R.O. report to view the information.
Registered Capital:
Purchase the Dr.Max 41 S.R.O. report to view the information.
Financial Auditors:
Purchase the Dr.Max 41 S.R.O. report to view the information.
Incorporation Date:
March 20, 2014
Key Executives
Purchase this report to view the information.
Legal Representative
Purchase this report to view the information.
Legal Representative
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Dr.Max 41 S.R.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
22.89%▲
Total operating revenue
22.88%▲
Operating profit (EBIT)
69.73%▲
EBITDA
61.11%▲
Net Profit (Loss) for the Period
78.06%▲
Total assets
0.26%▲
Total equity
19.31%▲
Operating Profit Margin (ROS)
0.53%▲
Net Profit Margin
0.44%▲
Return on Equity (ROE)
5.34%▲
Debt to Equity Ratio
-0.53%▼
Quick Ratio
0.11%▲
Cash Ratio
0%

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo